These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17691920)

  • 1. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed.
    Caccia S
    Curr Drug Metab; 2007 Aug; 8(6):612-22. PubMed ID: 17691920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vivo metabolism of 4-substituted arylpiperazines to pharmacologically active 1-arylpiperazines.
    Caccia S
    Boll Chim Farm; 1990 May; 129(5):183-9. PubMed ID: 1982054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
    Bauman JN; Frederick KS; Sawant A; Walsky RL; Cox LM; Obach RS; Kalgutkar AS
    Drug Metab Dispos; 2008 Jun; 36(6):1016-29. PubMed ID: 18332080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone.
    Staack RF; Maurer HH
    J Anal Toxicol; 2003; 27(8):560-8. PubMed ID: 14670134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of post-clozapine antipsychotics: pharmacological implications.
    Caccia S
    Clin Pharmacokinet; 2000 May; 38(5):393-414. PubMed ID: 10843459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilicity and disposition of 1-aryl-piperazines in the rat.
    Caccia S; Conti I; Notarnicola A; Urso R
    Xenobiotica; 1987 May; 17(5):605-16. PubMed ID: 3604264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
    Leopoldo M; Lacivita E; De Giorgio P; Fracasso C; Guzzetti S; Caccia S; Contino M; Colabufo NA; Berardi F; Perrone R
    J Med Chem; 2008 Sep; 51(18):5813-22. PubMed ID: 18800769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
    Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
    Prakash C; Kamel A; Anderson W; Howard H
    Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
    Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
    Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.
    Chouinard G; Lefko-Singh K; Teboul E
    Cell Mol Neurobiol; 1999 Aug; 19(4):533-52. PubMed ID: 10379424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
    Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
    Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
    Glennon RA; Naiman NA; Lyon RA; Titeler M
    J Med Chem; 1988 Oct; 31(10):1968-71. PubMed ID: 3172131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
    Wen B; Ma L; Rodrigues AD; Zhu M
    Drug Metab Dispos; 2008 May; 36(5):841-50. PubMed ID: 18238857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic metabolism of two alpha-1A-adrenergic receptor antagonists, phthalimide-phenylpiperazine analogs (RWJ-69205 and RWJ-69471), in the rat, dog and human.
    Wu WN; McKown LA; Kuo GH
    Eur J Drug Metab Pharmacokinet; 2006; 31(4):271-6. PubMed ID: 17315538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of new hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors. Part III.
    Herold F; Król M; Kleps J
    Acta Pol Pharm; 2004; 61(2):139-50. PubMed ID: 15493297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.
    Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
    Xenobiotica; 2004 Feb; 34(2):179-92. PubMed ID: 14985146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives).
    Murasaki M; Miura S
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):833-45. PubMed ID: 1355301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.